Horizon Investments LLC Sells 48,862 Shares of Abbott Laboratories $ABT

Key Points

• Horizon Investments cut its position in Abbott by 45.2%, selling 48,862 shares in Q4 and now holds 59,169 shares valued at $7.376 million per its SEC filing.
• Abbott slightly beat Q1 expectations with $1.15 EPS (vs. $1.14) and $11.16B revenue (up 7.8% YoY), and issued FY2026 guidance of EPS $5.38–5.58 and Q2 guidance of $1.25–1.31.
• The company announced a quarterly dividend of $0.63 (annualized $2.52, ~2.8% yield); institutional ownership is about 75.18% and analysts' consensus is a Moderate Buy with an average target of $119.43.

Horizon Investments LLC lessened its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 45.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 59,169 shares of the healthcare product maker's stock after selling 48,862 shares during the period. Horizon Investments LLC's holdings in Abbott Laboratories were worth $7,376,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Invesco Ltd. lifted its position in Abbott Laboratories by 51.0% during the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker's stock valued at $1,868,718,000 after acquiring an additional 4,713,135 shares during the period. Ninety One UK Ltd purchased a new stake in Abbott Laboratories in the fourth quarter worth about $336,815,000. Vanguard Group Inc. increased its stake in shares of Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker's stock valued at $21,995,501,000 after purchasing an additional 2,402,408 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Abbott Laboratories by 51.0% during the third quarter. Alliancebernstein L.P. now owns 5,525,906 shares of the healthcare product maker's stock valued at $740,140,000 after purchasing an additional 1,865,250 shares during the last quarter. Finally, Capital International Investors boosted its position in shares of Abbott Laboratories by 2.5% in the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker's stock worth $8,251,974,000 after purchasing an additional 1,478,076 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Performance

Shares of ABT opened at $89.51 on Friday. The company has a market cap of $155.90 billion, a price-to-earnings ratio of 25.07, a P/E/G ratio of 1.49 and a beta of 0.66. The business's fifty day simple moving average is $104.33 and its two-hundred day simple moving average is $116.09. Abbott Laboratories has a 12 month low of $89.14 and a 12 month high of $139.06. The company has a current ratio of 1.39, a quick ratio of 1.18 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion during the quarter, compared to analysts' expectations of $10.99 billion. During the same quarter in the previous year, the business earned $1.09 earnings per share. The company's revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.8%. Abbott Laboratories's dividend payout ratio is currently 70.59%.

Insider Activity

In other news, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the sale, the executive vice president directly owned 104,291 shares in the company, valued at $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares of the company's stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have bought 22,200 shares of company stock worth $2,215,100 and have sold 3,055 shares worth $353,097. 0.46% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ABT. BTIG Research reaffirmed a "buy" rating and set a $131.00 price objective on shares of Abbott Laboratories in a research report on Monday, April 27th. Bank of America cut their target price on Abbott Laboratories from $150.00 to $120.00 and set a "buy" rating on the stock in a research note on Friday, April 17th. Evercore reduced their price target on Abbott Laboratories from $134.00 to $120.00 and set an "outperform" rating for the company in a report on Friday, April 17th. Benchmark dropped their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating on the stock in a research note on Friday, April 17th. Finally, Mizuho cut their price objective on shares of Abbott Laboratories from $125.00 to $115.00 and set a "neutral" rating on the stock in a research report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of "Moderate Buy" and an average price target of $119.43.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.